Cambridge Cognition Holdings (LON:COG) has been reiterated to Corporate in a statement by finnCap earlier today.
- Updated: October 15, 2016
finnCap has reiterated Cambridge Cognition Holdings (LON:COG) to Corporate in a statement released on Thursday October 13, 2016.
On 9/29/2016, finnCap released a statement for Cambridge Cognition Holdings (LON:COG) maintained the target price at 115.00GBX that suggested an upside of 0.39%.
Boasting a price of 82.00GBX, Cambridge Cognition Holdings (LON:COG) traded -0.62% lower on the day. With the last stock price close up 67.17% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Cambridge Cognition Holdings has recorded a 50-day average of 71.91GBX and a two hundred day average of 47.86GBX. Volume of trade was down over the average, with 6,000 shares of COG changing hands under the typical 43,722
With a total market value of 0 GBX, Cambridge Cognition Holdings has with a one year low of 30.00GBX and a one year high of 97.00GBX .
A total of 1 equity analyst has released a ratings update on COG. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of 100.00GBX.
Brief Synopsis About Cambridge Cognition Holdings (LON:COG)
Cambridge Cognition Holdings plc and its subsidiaries develop and commercialize computerized neuropsychological tests for sale, principally in the United Kingdom, the United States and Europe. The Company's segments include Pharmaceutical Clinical Trials, Academic Research and Healthcare Technology. The Pharmaceutical Clinical Trials segment includes products and services for use in regulated pharmaceutical clinical trials. The Academic Research segment includes cognitive test products for researchers working in a non-regulated environment, typically in academia. The Healthcare Technology segment includes medical software for use in healthcare delivery settings. The Company is a provider of validated touchscreen cognitive assessments for clinical trials. The Company's product, CANTAB Mobile is a Class II medical device, used to identify patients exhibiting the early signs of Alzheimer's disease. It also offers Cantab Insight for dementia assessment in secondary care.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.